Dr. Peter Doshi: Vaccine Mandates

Dr. Bret Weinstein: ‘Perverse Incentives’ in the Vaccine Rollout and the Censorship of Science

Dr. Robert Malone, Inventor of mRNA Vaccine warns about the risks of the experimental vaccines

Dr. Aseem Malhotra, “Covid-19 vaccines rollout must stop immediately until raw data has been released for fully independent scrutiny”

Dr. Mark Trozzi: When will health regulators follow the science?

Dr. James Thorp: Increased Risk of Menstrual Abnormalities & Miscarriages After Vaccine

Dr. Stephanie Seneff: mRNA Vaccines and the Risk of Prion Disease

Dr. William Makis: Testimony to National Citizens Inquiry (NCI)

Dr. Ben Edwards’s Testimony to Texas Senate Health and Human Services Committee

Dr. Scott Youngblood: Efficacy of COVID Vaccines

Dr. Ryan Cole: Covid-19 Vaccine & ADE

Dr. Vladimir Zelenko: Covid-19 Vaccine

Dr. Geert Vanden Bossche: Mass Vaccination in a Pandemic – Benefits versus Risks (McMillan Research)

Dr. Peter McCullough: COVID Vaccine Agenda & The Rush To Suppress Alternative Treatments

Dr. Mike Yeadon, Former CSO & VP Allergy Respiratory Research Pfizer Global

Dr. Roger Hodkinson: How governments responded to COVID

Dr. Richard Fleming: Covid-19 Vaccine

Dr. Harvey Risch: Covid Taboos

Dr. Jenny Harries, Deputy CMO for England: Children are at greater risk from flu or road accidents than COVID-19

Dr. Meryl Nass: Myocarditis – The one they couldn’t hide

Dr. Charles Hoffe: Children and COVID Vaccines

Dr. Paul Marik: Covid Exposed A Corrupt Medical System

Dr. Tess Laurie, “These are not vaccines and the studies were not done”

Dr. Rochagné Kilian: Covid-19 Vaccines and D-Dimer Levels

Dr. Scott Jensen, “You’re Being Played”

Dr. Scott Atlas: They killed people with their lies

Dr. Suneel Dhand: Completely SAFE and 98 Percent EFFECTIVE

Dr. Jayanta Bhattacharya: There Was Never a Scientific Consensus on Lockdowns, Masks, or the Vaccine.

Dr. Chris Martenson: Midazolam Murders – When a Common Sedative Becomes an Execution Drug

Dr. Julie Ponesse: ETHICS 101

Prof. Fukushima Condemns mRNA Vaccines as ‘Evil Practices of Science’

Prof. Masayasu Inoue: A Message from Japan to the World

Prof. Luc Montagnier, “It is the vaccination that is creating the variants”

Prof. Sucharit Bhakdi: Perspectives on the Pandemic

Prof. Retsef Levi, MIT Professor & expert on drug safety, calls for an immediate suspension of all Covid mRNA vaccines

Prof. Michael Levitt: Does the data support the lockdown policy?

Prof. Carl Heneghan: Can we trust Covid-19 death numbers?

Prof. Norman Fenton: How flawed statistics have manipulated the Covid narrative

Prof. Denis Rancourt, The Elephant in the Room: C-19 Vaccines All-Cause Mortality

Prof. Mattias Desmet: Mass Formation Psychosis

Children Have 0.00% Chance of Dying from COVID but are Harmed for Life by Social Distancing

Why are we vaccinating children against COVID-19?
“The bulk of the official COVID-19-attributed deaths per capita occur in the elderly with high comorbidities, and the COVID-19 attributed deaths per capita are negligible in children. A novel best-case scenario cost-benefit analysis showed very conservatively that there are five times the number of deaths attributable to each inoculation vs those attributable to COVID-19 in the most vulnerable 65+ demographic. The risk of death from COVID-19 decreases drastically as age decreases, and the longer-term effects of the inoculations on lower age groups will increase their risk-benefit ratio.”

Age-stratified infection fatality rate of COVID-19 in the non-elderly population:
“At a global level, pre-vaccination IFR may have been as low as 0.03% and 0.07% for 0–59 and 0–69 year old people, respectively.”

COVID vaccination and age-stratified all-cause mortality risk:
“The risks of COVID vaccines and boosters outweigh the benefits in children, young adults and older adults with low occupational risk or previous coronavirus exposure.”

CDC Admits Crushing Rights of Naturally Immune Without Proof They Transmit the Virus

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

Persistent immune memory of COVID-19 found in recovered patient T cells

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

COVID-19 Natural Immunity

Comparing SARS-CoV-2 Natural Immunity to Vaccine-Induced Immunity: Reinfections Versus Breakthrough Infections

COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals
“This multi-country analysis confirmed pre-established safety signals for myocarditis, pericarditis, Guillain-Barré syndrome, and cerebral venous sinus thrombosis.”

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis

BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis
“Male patients ages 12-17 years have an elevated risk of mRNA vaccination-associated myo/pericarditis. A risk-benefit analysis of first and second doses of mRNA vaccination in adolescent boys by health status and history of SARS-CoV-2 infection has not been performed.”

Covid-19 Vaccine Adverse Reactions – Strong Association With Cardiovascular Death

MRNA COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance:
PAXLOVID includes ritonavir, a strong CYP3A inhibitor, which may lead to greater exposure of certain concomitant medications, resulting in potentially severe, life-threatening, or fatal events. Severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with PAXLOVID. Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Because nirmatrelvir is coadministered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection. Systemic exposure of nirmatrelvir increases in renally impaired patients with increase in the severity of renal impairment. Available data on the use of nirmatrelvir during pregnancy are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. There are no available data on the presence of nirmatrelvir in human or animal milk, the effects on the breastfed infant, or the effects on milk production. Authorized or approved mRNA COVID-19 vaccines show increased risks of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart), particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age.

“There is limited experience with use of COVID-19 mRNA vaccine in pregnant women. The safety profile of the vaccine is not yet fully known in pregnant or breastfeeding women due to their initial exclusion from the pivotal clinical study. It is unknown whether COVID-19 mRNA vaccine is excreted in human milk. The safety profile of the vaccine is not known in immunocompromised individuals due to their exclusion from the pivotal clinical study. There is limited information on the safety of the vaccine in individuals with autoimmune or inflammatory disorders and a theoretical concern that the vaccine may exacerbate their underlying disease. There is limited information on the safety of the vaccine in frail patients with co-morbidities who are potentially at higher risk of severe COVID-19. Events of Myocarditis and Pericarditis have been reported. Post-authorization reports have been reported more frequently in adolescent and young adult male patients following the second dose of vaccine; however, reports have been received for adult males and females of broader age range and following the first vaccination also. The long-term safety of COVID-19 mRNA vaccine is unknown at present.”

“Two novel excipients are included in the finished product, the cationic lipid ALC-0315 and the PEGylated lipid ALC-0159. ALC-0315 and ALC-0159 are novel excipients, not previously used in an approved finished product within EU. Some uncertainties remain regarding the ALC-0315 long half-life. Lipid related impurities have been observed in some recently manufactured finished product batches. Data demonstrate the presence of significant amounts of truncated/modified forms of mRNA at somewhat higher levels in the batches manufactured with the commercial process as compared to material used in clinical trials. No traditional pharmacokinetic or biodistribution studies have been performed with the vaccine candidate BNT162b2. No genotoxicity nor carcinogenicity studies have been provided. Several literature reports indicate that LNP-formulated RNAs can distribute rather non-specifically to several organs such as spleen, heart, kidney, lung and brain.”

“There is an increased risk of myocarditis and pericarditis following vaccination with Comirnaty. These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days. They have been observed more often after the second vaccination, and more often in younger males. Some cases required intensive care support and fatal cases have been observed. No Comirnaty data are available on vaccine placental transfer or excretion in milk. Neither genotoxicity nor carcinogenicity studies were performed.”

“Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For COMIRNATY, the observed risk is highest in males 12 through 17 years of age. COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. Available data on COMIRNATY administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. It is not known whether COMIRNATY is excreted in human milk. Data are not available to assess the effects of COMIRNATY on the breastfed infant or on milk production/excretion.”

“Causal association between Spikevax and myocarditis is considered of at least a reasonable possibility. The majority of the cases have been reported in young males, and shortly after the second dose of the vaccine. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.”

“The review of the data received during the reporting review showed that the events of myocarditis and pericarditis continue to primarily occur in young adult males, shortly after the second dose of the vaccine with a TTO less than 7 days. The same pattern was observed for cases reported after receiving a booster dose of Spikevax.”

“There is an increased risk for myocarditis and pericarditis following vaccination with Spikevax. These conditions can develop within just a few days after vaccination, and have primarily occurred within 14 days. They have been observed more often in younger males, and more often after the second dose compared to the first dose. Some cases required intensive care support and fatal cases have been observed. No data are available of Spikevax vaccine placental transfer or excretion in milk. Carcinogenicity studies were not performed.”

Moderna SPIKEVAX (COVID-19 Vaccine, mRNA):
“Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. For SPIKEVAX, the observed risk is highest in males 18 years through 24 years of age. Information is not yet available about potential long-term sequelae. SPIKEVAX has not been evaluated for carcinogenic, mutagenic potential, or impairment of male fertility. Available data on SPIKEVAX administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. It is not known whether SPIKEVAX is excreted in human milk. Data are not available to assess the effects of SPIKEVAX on the breastfed infant or on milk production/excretion.”

Moderna mRNA Platform ‘The Software of Life’:
“mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines. Gene therapies and mRNA based medicines may activate one or more immune responses against any and all components of the drug product (e.g. the mRNA or the delivery vehicle, such as a lipid nanoparticle) as well as against the encoded protein, giving rise to potential immune reaction related adverse events. Most of our investigational medicines are formulated and administered in an LNP which may lead to systemic side effects related to the components of the LNP which may not have ever been tested in humans.”

Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease:
“The specific and significant COVID-19 risk of ADE should have been and should be prominently and independently disclosed to research subjects currently in vaccine trials, as well as those being recruited for the trials and future patients after vaccine approval, in order to meet the medical ethics standard of patient comprehension for informed consent.”

Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines:
“Historically, vaccine research has been focused on whether or not vaccination could generate neutralizing antibodies to protect against viral infections, whereas short-term and long-term influences of the various newly developed vaccines to human pathophysiology and other perspectives of the human immune system have not been fully investigated.”
IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein:
“Recent investigations have found abnormally high levels of IgG4 in people who were administered two or more injections of the mRNA vaccines. Emerging evidence suggests that the reported increase in IgG4 levels detected after repeated vaccination with the mRNA vaccines may not be a protective mechanism; rather, it constitutes an immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses. Increased IgG4 synthesis due to repeated mRNA vaccination with high antigen concentrations may also cause autoimmune diseases, and promote cancer growth and autoimmune myocarditis in susceptible individuals.”

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory:
“In summary, here we show that the LNPs used for many preclinical studies are highly inflammatory. Thus, their potent adjuvant activity and reported superiority comparing to other adjuvants in supporting the induction of adaptive immune responses likely stem from their inflammatory nature. Furthermore, the preclinical LNPs are similar to the ones used for human vaccines, which could also explain the observed side effects in humans using this platform.”

Spikeopathy: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
“The inflammatory properties of the nanoparticles used to ferry mRNA; N1-methylpseudouridine employed to prolong synthetic mRNA function; the widespread biodistribution of the mRNA and DNA codes and translated spike proteins, and autoimmunity via human production of foreign proteins, contribute to harmful effects.”

SARS–CoV–2 Spike Protein Impairs DNA Damage Repair:
“Our findings reveal a potential molecular mechanism by which the spike protein might impede adaptive immunity and underscore the potential side effects of full-length spike-based vaccines.”

Pfizer-BioNTech COVID-19 Vaccine (PAGE 25):
“BNT162 vaccines have not been administered to humans before and thus there are no previous clinical data with these specific vaccines.”

Pfizer Documents the FDA Tried to Hide Shows LNPs from COVID-19 Vaccine Travel Everywhere in the Body

Urgent Expert Hearing on Reports of DNA Contamination in mRNA Vaccines

Worse than the Disease? Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID-19

COVID-19 RNA Based Vaccines and the Risk of Prion Disease

New Quality-Control Investigations on Vaccines: Micro and Nanocontamination
“We verified the presence of saline and Aluminum salts, but further presence of micro, sub-micro and nanosized, inorganic, foreign bodies (ranging from 100nm to about ten microns) was identified in all cases, whose presence was not declared in the leaflets delivered in the package of the product.”

Cause of Death After COVID-19 Vaccination: Undeclared Components of the COVID-19 Vaccines

Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination

AAPS Statement: Mask Mandates Do Not Prevent Spread of Respiratory Viruses, They Cause Harm, and Violate the Right to Informed Consent

Scroll to Top